Key Takeaways GSK's Q2 core EPS of $1.23 and$10.67 billion revenues beat estimates on strong product demand.Specialty Medicines rose 15% and Vaccines 9%, offsetting General Medicines' 6% decline.GSK raised 2025 sales and profit guidance toward the top end of prior forecasts.GSK plc (GSK) reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks Consensus Estimate of$1.12. Core earnings increased 7% year over year on a reported basis and 15% at a constant ...